相关实验视频

Updated: Jul 5, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

特里普托利德通过调节circNOX4/miR-153-3p/SATB1信号通路来抑制食道状细胞癌的进展

Hanping Liang¹, Weibi Che¹, Fengyuan Peng¹

¹Department of thoracic surgery, Gaozhou people's Hospital, Gaozhou, China.

Thoracic cancer

|January 25, 2024

概括

特里普托利德通过调节circNOX4/miR-153-3p/SATB1通路来抑制食道状细胞癌 (ESCC) 的进展. 这项研究揭示了triptolide的新型机制.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
基因规则基因规则

背景情况:

食道状细胞癌 (ESCC) 是一种流行癌症,具有复杂的进展机制.
循环RNAs (circRNAs) 越来越多地被认为是各种癌症的关键调节者,包括ESCC.
一种天然化合物,Triptolide在癌症治疗中显示出潜力,但其在ESCC中的精确作用需要阐明.

研究的目的:

调查三类在ESCC进展中的作用.
阐明涉及循环RNA路径的潜在分子机制.
为了确定ESCC的三类介导调节中的关键分子参与者.

主要方法:

定量实时PCR (qRT-PCR) 用于基因表达分析.
细胞增殖,细胞亡,细胞循环,迁移和入侵测试.
西方斑点用于蛋白质水平的确定.
双露西法酶记者和RNA免疫沉降 (RIP) 试验用于相互作用确认.
异种移植瘤模型用于体内验证.

主要成果:

在ESCC中,CircNOX4的表达升高,而在triptolide中则降低.
托利德抑制ESCC的扩散,迁移,入侵和EMT,同时促进细胞亡.
通过CircNOX4的过度表达,可以逆转triptolide的抑制作用.
托利德通过circNOX4/miR-153-3p/SATB1轴作用,调节ESCC的进展.

结论:

三托利德有效地阻碍了ESCC的进展.
在ESCC中,circNOX4/miR-153-3p/SATB1轴是一个关键的途径,它调解了triptolide在ESCC中的抗癌作用.
这项研究为triptolide作为ESCC的潜在治疗剂提供了分子基础.

关键词:

在SATB1中,SATB1是SATB1.这就是circNOX4的原因.食管状细胞癌的癌症在 miR-153-3pp 中.类三类化物

更多相关视频

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...